Thymoquinone in Atherosclerosis: A Multi-Target Nutraceutical Modulating Inflammation, Oxidative Stress, and Lipid Metabolism.

Abstract

<p>BACKGROUND: Atherosclerosis is a chronic inflammatory disease driven by complex interactions between lipid metabolism disorders, oxidative stress, and immune dysregulation. Despite advances in pharmacotherapy, there is growing interest in nutraceutical compounds with multi-target effects. Thymoquinone (TQ), the main bioactive constituent of Nigella sativa, has emerged as a promising candidate due to its anti-inflammatory, antioxidant, and lipid-modulating properties. This review aims to comprehensively evaluate the effects of TQ on the key pathophysiological mechanisms involved in atherosclerosis, with particular emphasis on inflammation, oxidative stress, and lipid metabolism. METHODS: A narrative review of preclinical studies, including in vitro and in vivo experimental models, was conducted to assess the biological activity of TQ and its potential anti-atherosclerotic effects. RESULTS: TQ exhibits multi-target activity by modulating several molecular pathways associated with atherogenesis. It reduces oxidative stress by enhancing antioxidant enzyme activity and decreasing reactive oxygen species production. TQ also suppresses inflammatory signaling pathways, including NF-κB, MAPK, and COX-2, leading to decreased expression of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. Furthermore, it influences lipid metabolism by lowering total cholesterol and LDL-C levels while improving lipid profiles. TQ has also been shown to inhibit foam cell formation, endothelial dysfunction, and vascular inflammation. Additionally, nanocarrier-based formulations of TQ may improve its bioavailability and therapeutic potential. CONCLUSIONS: Current preclinical evidence suggests that TQ may play a significant role in the prevention and modulation of atherosclerosis through its multi-mechanistic action. However, the lack of well-designed clinical trials, limited bioavailability, and insufficient data on long-term safety highlight the need for further research to establish its clinical efficacy and optimal therapeutic use.</p>